About this item:

130 Views | 145 Downloads

Author Notes:

Corresponding Author: Deirdre A. Hill, Department of Internal Medicine, University of New Mexico School of Medicine, MSC 10 5550, 1 University of New Mexico, Albuquerque, NM 87131-0001, (w) (505) 272-5469 (f) (505) 272-8572, dahill@salud.unm.edu.

We would like to thank Ms. Kimberly Cooke, Mr. Nicolas Eldredge, Ms. Rebecca Sando, Ms. Chanel Jim, Mr. Francisco Martinez, Ms. Nancy Brito, and Ms. Georgia Hufnagel for their assistance in conducting this study.

The authors declare that they do not have a conflict of interest in connection with this manuscript.

Subjects:

Research Funding:

This study was supported by grants R01CA132877 and 2P30CA11810 from the National Cancer Institute (NCI) and NCI contract HSN26120130010I-Task Order HHSN26100005 to the Surveillance Epidemiology End Results (SEER) program.

Breast cancer survival, survival disparities, and guideline-based treatment

Tools:

Journal Title:

Breast Cancer Research and Treatment

Volume:

Volume 170, Number 2

Publisher:

, Pages 405-414

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Purpose: The role of appropriate therapy in breast cancer survival and survival disparities by race/ethnicity have not been fully elucidated. We investigated whether guideline-inconsistent therapy contributed to survival differences overall and among Hispanics relative to non-Hispanic white (NHW) women in a case-cohort study. Methods: This study included a 15% random sample of female invasive breast cancer patients diagnosed from 1997–2009 in 6 New Mexico counties and all deaths due to breast cancer-related causes. Information was obtained from comprehensive medical chart reviews. National Comprehensive Cancer Network (NCCN®) guideline-consistent treatment was assessed among white women aged < 70 who were free of contraindications for recommended therapy, had stage I–III tumors, and had survived at least 12 months. Hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer death were estimated using Cox proportional hazards models. Results: The median survival was 101 months. The included women represented 4635 patients and 449 breast cancer deaths. Women who met specific NCCN treatment criteria but did not receive radiotherapy (HR 2.3; 95% CI 1.2–4.4) or endocrine therapy (HR 2.0; 95% CI 1.0–4.0) had an increased risk of breast cancer death relative to those who did receive these therapies. Guideline-consistent therapy receipt did not differ between Hispanic and NHW women for chemotherapy (84.2% vs. 81.3%, respectively), radiotherapy (89.2% vs. 91.1%, respectively) or endocrine therapy (89.2% vs. 85.8%, respectively), and it did not influence Hispanic survival disparities. Conclusions: Guideline-concordant receipt of radiotherapy and endocrine therapy contributed to survival as strongly as other established prognostic indicators. Hispanic survival disparities in this population do not appear to be attributable to treatment differences.

Copyright information:

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Export to EndNote